I’m aware of three expected scheduled readouts - but there may be some new surprise IE collaboration as in the new lymphoma study recently announced:
in practicality we have our phase 3 pivotal study starting, but,
in theory we can be approved in any one condition at phase 2 and we - x3 phase 2 Studies underway and with one more about to start in January
———
many drugs have been approved in phase 2 data alone...lung cancer drug, ceritinib, received approval based on Phase 2 trial results showing an overall response rate for more than half of patients over seven months....
paxalisib works in 65+% of patients and extends life by 61.5% over the current standard of care Temozolomidehttps://www.appliedclinicaltrialsonline.com/view/impact-faster-drug-approvals-oncology-clinical-trial-design———
1out of 8 drugs which are new orphan drugs or cancer drugs approved on one trial Most recently, IQVIA released a report finding that 25 of 59 (42%) novel drugs approved in 2018 were approved on the basis of only one trial. And one out of eight approvals relied only on Phase 1 or 2 trials, with no Phase 3 trials. But as in previous years, a large portion of the drugs relying on only one trial were new orphan and cancer drugs.
Paxalisib has a new orphan drug designation and is About to be x4 phase 2 trials... multiple shots on goal!
https://www.raps.org/news-and-articles/news-articles/2019/5/almost-half-of-all-new-drug-approvals-in-2018-reliThese very exciting times for holders of Kazia with paxalisib in multiple phase 1 and phase 2 trials with an orphan drug designation and a potential PRV worth hundreds of millions in compensation
its taken years to get here and the market has not yet caught up with where we are at - but it will eventually - as we are fully funded through our new phase trial and the next couple of years as per the recent Excellent interview we have all seen
